The efficacy of Telisotuzumab in the treatment of non-small cell lung cancer

Telisotuzumab (Telisotuzumab Vedotin, trade name Emrelis) is an antibody-conjugated drug targeting c-Met protein, specifically used to treat non-small cell lung cancer (NS CLC) patients, especially those with high c-Met expression and EGFR wild-type advanced non-squamous NSCLC patients. The drug targets the c-Met protein on the surface of tumor cells and delivers cytotoxic drugs directly to cancer cells, thereby achieving precise killing and reducing damage to normal tissues.

In the pivotalLUMINOSITY II phase clinical trial, terituzumab demonstrated promising efficacy. Research data shows that the objective response rate (ORR) of patients with high c-Met expression reaches 34.6%, and the median sustained response time (ORR pan>DOR) is about 9 months, and the disease control rate (DCR) exceeds 60%. In addition, patients' progression-free survival (PFS) and overall survival (OS) also showed positive improvements, indicating that the drug has clear advantages in controlling disease progression.

Subgroup analyzes in the Asian patient population were equally encouraging. c-MetAsian patients with high expression of c-MetORR reached 58%, and the median response duration was approximately 6.9 months, showing better efficacy. This shows that terituzumab has a stable therapeutic effect in patients with non-small cell lung cancer of different races and regions, broadening the application potential of the drug in the global market.

In terms of safety, territuzumab was generally well tolerated. Common adverse reactions include peripheral neuropathy, peripheral edema and fatigue, most of which are mild to moderate, and the incidence of serious adverse events is low. Although there were a few serious adverse events, the overall safety assessment supported its clinical use. In summary, territuzumab isc-MetHigh expression of c-Met has brought new effective treatment options to patients with non-small cell lung cancer and is expected to become an important targeted drug in this field in the future.

Reference materials:https://www.drugs.com/